Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/FOS_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FOS_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FOS_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FOS_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FOS_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FOS_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/FOS_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FOS_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FOS_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FOS_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FOS_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FOS_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FOS_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000961519 | Skin | AK | response to virus | 63/1910 | 367/18723 | 2.53e-05 | 4.54e-04 | 63 |
GO:000961217 | Skin | AK | response to mechanical stimulus | 42/1910 | 216/18723 | 3.07e-05 | 5.21e-04 | 42 |
GO:003166824 | Skin | AK | cellular response to extracellular stimulus | 46/1910 | 246/18723 | 3.67e-05 | 6.11e-04 | 46 |
GO:00325709 | Skin | AK | response to progesterone | 13/1910 | 37/18723 | 4.21e-05 | 6.70e-04 | 13 |
GO:190210515 | Skin | AK | regulation of leukocyte differentiation | 50/1910 | 279/18723 | 5.47e-05 | 8.35e-04 | 50 |
GO:000257318 | Skin | AK | myeloid leukocyte differentiation | 40/1910 | 208/18723 | 6.06e-05 | 9.01e-04 | 40 |
GO:190289319 | Skin | AK | regulation of pri-miRNA transcription by RNA polymerase II | 16/1910 | 54/18723 | 6.27e-05 | 9.23e-04 | 16 |
GO:004563726 | Skin | AK | regulation of myeloid cell differentiation | 40/1910 | 210/18723 | 7.55e-05 | 1.06e-03 | 40 |
GO:00147069 | Skin | AK | striated muscle tissue development | 62/1910 | 384/18723 | 1.79e-04 | 2.06e-03 | 62 |
GO:19028959 | Skin | AK | positive regulation of pri-miRNA transcription by RNA polymerase II | 13/1910 | 42/18723 | 1.85e-04 | 2.12e-03 | 13 |
GO:000926620 | Skin | AK | response to temperature stimulus | 34/1910 | 178/18723 | 2.38e-04 | 2.61e-03 | 34 |
GO:190121626 | Skin | AK | positive regulation of neuron death | 22/1910 | 97/18723 | 2.51e-04 | 2.72e-03 | 22 |
GO:004668319 | Skin | AK | response to organophosphorus | 27/1910 | 131/18723 | 2.87e-04 | 3.00e-03 | 27 |
GO:000717817 | Skin | AK | transmembrane receptor protein serine/threonine kinase signaling pathway | 57/1910 | 355/18723 | 3.69e-04 | 3.61e-03 | 57 |
GO:003249620 | Skin | AK | response to lipopolysaccharide | 55/1910 | 343/18723 | 4.79e-04 | 4.44e-03 | 55 |
GO:000717910 | Skin | AK | transforming growth factor beta receptor signaling pathway | 35/1910 | 198/18723 | 8.69e-04 | 7.17e-03 | 35 |
GO:00510909 | Skin | AK | regulation of DNA-binding transcription factor activity | 66/1910 | 440/18723 | 8.99e-04 | 7.40e-03 | 66 |
GO:001407419 | Skin | AK | response to purine-containing compound | 28/1910 | 148/18723 | 9.46e-04 | 7.63e-03 | 28 |
GO:00027618 | Skin | AK | regulation of myeloid leukocyte differentiation | 24/1910 | 120/18723 | 9.53e-04 | 7.64e-03 | 24 |
GO:00075658 | Skin | AK | female pregnancy | 34/1910 | 193/18723 | 1.09e-03 | 8.48e-03 | 34 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0465716 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0532312 | Breast | Precancer | Rheumatoid arthritis | 19/684 | 93/8465 | 1.30e-04 | 1.14e-03 | 8.73e-04 | 19 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa05031 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0493217 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SAPONIN | | 12451485 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | BACLOFEN | BACLOFEN | 11301212 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ANTI-INFLAMMATORY DRUGS | | 11164833 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | INTERLEUKIN-1-BETA | | 8677009 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PROTEIN KINASE A INHIBITOR | | 9093533 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | THROMBIN | THROMBIN | 2119237 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | MAPK INHIBITORS | | 14511403 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | BETA-INTERFERON | | 2491749 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PACLITAXEL | PACLITAXEL | 9588740 |
2353 | FOS | TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | MAGNESIUM SULFATE | | 11336444 |